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Abstract
Haemoglobin degradation during the erythrocytic life stages is the major function of the food vacuole (FV) of Plasmodium
falciparum and the target of several anti-malarial drugs that interfere with this metabolic pathway, killing the parasite. Two
multi-spanning food vacuole membrane proteins are known, the multidrug resistance protein 1 (PfMDR1) and Chloroquine
Resistance Transporter (PfCRT). Both modulate resistance to drugs that act in the food vacuole. To investigate the formation
and behaviour of the food vacuole membrane we have generated inducible GFP fusions of chloroquine sensitive and
resistant forms of the PfCRT protein. The inducible expression system allowed us to follow newly-induced fusion proteins,
and corroborated a previous report of a direct trafficking route from the ER/Golgi to the food vacuole membrane. These
parasites also allowed the definition of a food vacuole compartment in ring stage parasites well before haemozoin crystals
were apparent, as well as the elucidation of secondary PfCRT-labelled compartments adjacent to the food vacuole in late
stage parasites. We demonstrated that in addition to previously demonstrated Brefeldin A sensitivity, the trafficking of
PfCRT is disrupted by Dynasore, a non competitive inhibitor of dynamin-mediated vesicle formation. Chloroquine sensitivity
was not altered in parasites over-expressing chloroquine resistant or sensitive forms of the PfCRT fused to GFP, suggesting
that the PfCRT does not mediate chloroquine transport as a GFP fusion protein.
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Introduction
The parasite Plasmodium falciparum is the causative agent of
severe malaria in humans, killing somewhere between 600,000
and 1.2 million people each year [1,2]. The complex life cycle
includes an asexual proliferation within human erythrocytes,
characterised by three distinct stages: rings, trophozoites and
schizonts. Adaptations to the intra-erythrocytic lifestyle have
created new and in some cases unique organelles, such as an
endosomal/lysosomal-like organelle, the food vacuole (FV)
(reviewed in [3]).
In contrast to other organelles, such as the mitochondrion and
the apicoplast [4], the FV does not persist throughout the whole
asexual intra-erythrocytic life cycle, and is discarded at the end of
each cycle. Analysis by multiple laboratories has resulted in several
competing models for FV biogenesis during the ring stage. These
include 1) The ‘‘big gulp model’’, which suggests that the first step
in the FV biogenesis is an initial uptake of a single large parcel of
haemoglobin followed by a continuous uptake of packages
mediated by cytostomes that fuse, vesicle-like, with the FV. An
additional contribution of endocytosis is not excluded from this
model [5]. 2) The ‘‘tubus model’’ prefers the contribution of
cytostomes in the uptake of haemoglobin as well, yet in contrast to
the previous model this theory is vesicle-independent. In this
model, the cytostomes do not initially pinch-off but form elongated
tubes that eventually fuse with the FV. The tubes would initially
enable the uptake of haemoglobin through contact with the
cytostome, and then later deliver haemoglobin to the FV after
pinching off and fusing with the FV [6]. 3) The ‘‘pre-FV model’’ is
based on the observation that in early intra-erythrocytic life stages
multiple enclosed compartments, called pre-FV compartments,
are detectable in which haemoglobin degradation has already
started [7]. In late ring stages these smaller compartments fuse and
give rise to the FV in early trophozoite stages. Vesicles derived
from the cytostomal invagination are delivered to the FV to
continue supplying the organelle with haemoglobin [7].
The degradation of haemoglobin is still the only verified
function of the FV, and has been studied extensively [3]. The
protein component of haemoglobin is catabolised via series of
peptidases [8,9,10] but this degradation releases ferriprotopor-
phyrin IX (FP) which cannot be degraded by the malarial parasite
and is toxic. Instead, Plasmodium parasites polymerise FP to
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trophozoite and schizont parasites [11,12,13]. The crucial process
of FP polymerisation is the target of important antimalarial drugs.
The best understood of these inhibitory processes is that of
chloroquine (CQ), which accumulates in the FV and there inhibits
the polymerisation of haem into haemozoin, either by binding free
FP [14], or by capping FP polymers [15]. This results in
accumulation of toxic unpolymerised FP and toxic FP-CQ
complexes, although there is ongoing discussion of exactly how
these compounds mediate parasite death [16,17].
Chloroquine enters parasites in a neutral form that is believed to
diffuse across the food vacuole membrane, but inside the acidic
environment it is protonated and, once charged, is unable to freely
diffuse out of the FV again. This leads to an accumulation of
chloroquine inside the food vacuole, relative to the rest of the
parasite and the external milieu. Chloroquine resistant parasites
accumulate considerably less CQ in their FV relative to sensitive
parasites [18,19,20,21]. The difference in accumulation is
attributable to mutations in the FV membrane protein PfCRT
(PF3D7_0709000), particularly a substitution of K to T at residue
76 [22] and to a lesser degree, changes in the FV membrane
protein PfMDR1 (PF3D7_0523000) [23,24]. The means by which
PfCRT modulates FV chloroquine concentration has been much
debated, and some authors have suggested that a difference in the
pH of the FV between sensitive and resistant parasites modified
the accumulation of drug (eg [25]). However, more recent studies
indicate that sensitive and resistant parasites do not have
significantly different FV acidity [26], but that the modified
PfCRT in CQ resistant parasites directly facilitates a leak of
chloroquine out of the FV [27,28,29,30]. These data indicate that
mutations in PfCRT allow charged CQ to escape from the FV,
and that its efflux decreases the concentration of CQ in the FV to
non-lethal levels. Despite its clear association with resistance, it
remains unclear whether PfCRT mutations are sufficient to
generate chloroquine resistance in the field. In many chloroquine
resistant isolates, polymorphisms are also found in PfMDR1 and
other transporters [31], and regulatory changes in assorted other
genes have been associated with compensation for the resistance
mutations in PfCRT [32]. Even in isogenic lines, transfected
parasites take several weeks to reach population levels that allow
drug assays to be performed, potentially allowing lines to
compensate for PfCRT changes through secondary trans mutations
or epigenetic regulatory changes. To circumvent the necessarily
long delay between transfection and analysis of transgenic
parasites, and to characterise the direct effect of PfCRT mutations,
we generated isogenic parasites lines with anhydrotetracycline-
regulatable expression of PfCRT-GFP fusions, using pfcrt alleles
from sensitive (PfCRT
S) and resistant parasites (PfCRT
R).
Inducible expression of PfCRT-GFP fusions also allows us to
further characterise the trafficking of PfCRT to the FV
membrane. Our knowledge about the targeting of proteins
towards the FV has until recently been restricted to lumenal
proteases participating in haemoglobin degradation, such as
Plasmepsin II and DPAP1. The FV lumenal peptidase Plasmepsin
II is targeted via the parasite plasma membrane (PM) to the FV as
an integral membrane protein in a Brefeldin A (BFA)-sensitive
manner [8], whereas the soluble DPAP1 is first transported
through the PM, accumulating in the Parasitophorous vacuole
(PV), followed by the final transport step to the FV [8]. Recently
the first study of targeting for PfCRT was published, demonstrat-
ing that PfCRT traffic to the FV membrane is via the ER, is
Brefeldin A sensitive, and that subsequent direction to the FVM
depends on a small region at the C-terminus that includes a
potentially phosphorylated threonine (position 416) [33]. The key
PfCRT mutation associated with chloroquine resistance, K76T, is
positioned at the boundary of the protein’s first transmembrane
domain (TMD), and the length and composition of a protein’s
initial transmembrane length is a trafficking determinant in other
endomembrane proteins [34,35,36]. We therefore examined
whether the change of charge at the transmembrane boundary
of PfCRT affected the sub-cellular localisation and thus function of
the CQ-resistant form.
In this study we have taken advantage of an inducible
expression system in order to over-express both PfCRT
S and
PfCRT
R as GFP-tagged fusion proteins within CQ sensitive 3D7
Plasmodium parasites. We show that both PfCRT forms are
identically localised at the FV membrane, and that differential
subcellular localisation is therefore not a cause of differential
chloroquine sensitivity. We also show that PfCRT trafficking is
inhibited by Dynasore, an inhibitor of dynamin-mediated vesicle
formation, consistent with a role for dynamin in FV biogenesis.
The inducible GFP-tagged PfCRT also provides an excellent tool
to follow the biogenesis of the FV development. We show the
existence of a PfCRT enveloped organelle prior to the appearance
of haemozoin, the traditional definition of the appearance of FV.
Materials and Methods
Bioinformatic analysis
Sequence of the annotated PfCRT (PF3D7_0709000) was
acquired from PlasmoDB [37] (www.plasmodb.org). Characteris-
tic point mutations within the first TMD of PfCRT of the CQ-
sensitive strain D10 and CQ-resistant strains 7G8 and Dd2 were
obtained from Fidock et al. [22]. Alignments were performed
using ClustalW (by Jalview [38]). Prediction of TMD length and
position of PfCRT
S or PfCRT
R was carried out using the
predictors TMHMM2 [39] (www.cbs.dtu.dk/services/TMHMM),
MEMSAT [40] (http://saier-144-21.ucsd.edu/barmemsat.html)
and SPLIT4 [41] (http://split.pmfst.hr/split/4/). Sequence of the
first TMD of the glycoprotein M1 of the avian coronavirus
infectious bronchitis virus was obtained from Machamer et al.
[42]. Helical wheel projections were performed using the helical
wheel applet created by Edward K. O’Neil and Charles M.
Grisham (University of Virginia in Charlottesville, Virginia, USA).
Plasmid construction
Plasmid pT150HA was generated by replacing the MSP2
59UTR in pTMSP2HA that drives transcription of the TATi3
transactivator (a derivative of pTGFP that contains a dual
haemagglutinin epitpope in place of GFP [43,44] with that of
PTEX150 (PF3D7_1436300). For this, P. falciparum gDNA was
PCR amplified with the oligonucleotides PF0344-59F
(cggcttaagGTTGTTTTTCTCTTTG-TGGTCAAAATAAG)
and PF0344-59R (gctaatattattattctcatctcgagTTTTTTTTTTT-
TTTTAAATGTTGAATTATAAAC), and the resulting 1.55 kb
product was digested with AflII and XhoI and then filled in with
Klenow. This fragment was subsequently cloned into the XmaI/
BstB1 sites of pTMSP2HA that had also been filled in with
Klenow. The 2xHA epitope tag of pT150HA was then replaced
with GFP to create pT150GFP. This vector provides unique PstI
and MluI restriction enzyme sites between the minimal regulatable
promoter and GFP to create inducible GFP fusion proteins. To
create pT150KPfCRTGFP, sequences corresponding to the full-
length coding region of PfCRT (PF3D7_0709000) were amplified
from the chloroquine sensitive strain 3D7 (hereafter referred to as
PfCRT
S) and the chloroquine resistant 7G8 (hereafter referred to
as PfCRT
R), and directionally cloned into the PstI and MluI site of
pT150GFP.
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O+ human erythrocytes (Australian Red Cross Blood Service,
Melbourne, Australia) infected with P. falciparum parasites of the
3D7 or W2mef strain were cultured using a modification of the
method established by Trager and Jensen [45] as described in
[46]. Transfection of P. falciparum parasites was carried out as
previously described [47]. A total of 100 mg plasmid-DNA was
used per transfection and electroporated into ring-stage parasites.
P. falciparum parasites transfected with the inducible vector were
recovered in HEPES-buffered RPMI-1640 medium supplemented
with 3.6% sodium bicarbonate and 5% Albumax II (Invitrogen-
Gibco) containing the transcription inhibitor anhydrotetracycline
(ATc) (Sigma-Aldrich) at a final concentration of 0.5 mg/mL.
WR99210 was added 4–5 h post transfection to the complete
medium to a final concentration of 10 mM to select for parasites
with the plasmid. The cultures were incubated in an atmosphere of
5% CO2,1 %O 2, and 94% N2 at 37uC.
Protein expression from the ATc-repressible plasmid was
induced as follows: Parasite cultures were synchronised using 5%
sorbitol for 5 min at 37uC [48], and subsequently cultured in the
absence of the transcription inhibitor ATc for 48 h. Following this,
the parasitaemia was adjusted to 4–8% ring-stage parasites and
incubated for further 18–24 h. Protein expression of GFP-epitope
tagged proteins was checked using a Zeiss Axioplan 2 imaging
Universal Microscope (Zeiss). Parasites in which protein expres-
sion had been induced were discarded after use, and subsequent
experiments were performed with freshly induced parasites from a
population of never-induced parasites.
Western blot detection of overexpressed protein
Protein expression of GFP-tagged PfCRT was induced and total
protein from erythrocytes infected with mainly schizont parasites
was obtained by lysis with PBS containing 0.15% (w/v) saponin
and 0.1% (w/v) BSA for 10 min at 4uC in the presence of EDTA-
free protease inhibitor (Roche). Proteins from 1610
7 parasites
were heated for 30 min at 40uC in the presence of EDTA-free
protease inhibitor (Roche) and separated on a 10% Bis-Tris gel
with MOPS running buffer (Invitrogen). Proteins were transferred
to Hybond polyvinylidene fluoride (PVDF) membrane (GE
Healthcare Life Sciences). GFP-tagged PfCRT was identified with
mouse anti-GFP (1:500, Roche) followed by anti-mouse HRP-
conjugated IgG (1:5,000, Molecular Probes), while endogenous
GAPDH was identified with rabbit anti-GAPDH (1:5,000) (A kind
gift from Leann Tilley, University of Melbourne) followed by anti-
rabbit HRP-conjugated IgG (1:5,000, Molecular Probes) and
visualised using chemiluminescence system (ECL, Pierce).
Live cell imaging and immunofluorescence assays
Sample preparation of living cells was performed as follows:
Protein expression of GFP-tagged PfCRT was induced, erythro-
cytes infected with mainly trophozoite and schizont parasites were
harvested and the nuclei of the parasites stained with DAPI
Nucleic Acid stain (Invitrogen) (1:500) in PBS for 15 min at 4uC.
Cells were washed once with PBS and resuspended in 12 mL PBS.
Immunofluorescence assays (IFAs) were performed as previously
described [49]. Protein expression of GFP-tagged PfCRT was
induced and erythrocytes infected with mainly trophozoite and
schizont parasites were fixed for 50 min at room temperature (RT)
in PBS containing 4% (v/v) paraformaldehyde and 0.0075% (v/v)
glutaraldehyde, washed twice with ice-cold PBS, permeabilised
with 0.01% Triton X-100 in PBS for 10 min at RT and washed
with PBS. Cells were incubated with mouse anti-GFP (1:200,
Roche) antibody in 3% (w/v) BSA in PBS overnight at 4uC. Cells
were washed twice with and incubated with either Alexa Fluor
488- or Alexa Fluor 594-conjugated antibodies (1:500, Molecular
probes) in 3% (w/v) BSA in PBS for 1 h at 4uC. Washed cells were
incubated with DAPI Nucleic Acid stain (1:500, Invitrogen) in 3%
(w/v) BSA in PBS for 15 min at 4uC. Before mounting cells on a
glass slide, they were washed twice in PBS and eventually
resuspended in 12 mL PBS. A 5 mL aliquot of the resuspended
cells was mounted in 60% glycerol with DABCO (Sigma-Aldrich)
on a glass slide, covered with a cover slip coated with 0.01% or
0.1% Polyethylenimine for living cells or fixed cells, respectively,
and sealed. The cells were analysed using the Zeiss Axioplan 2
imaging Universal Microscope (Zeiss) and the imaging software
AxioVision v4.5 (Zeiss).
Brefeldin A and Dynasore treatment
Erythrocytes infected with P. falciparum parasites were treated
with either Brefeldin A (Sigma-Aldrich) as previously described [8]
or Dynasore hydrate (Sigma-Aldrich) as previously described [50].
Brefeldin A (5 mg/mL dissolved in 100% ethanol) was added to
young trophozoite or schizont parasites expressing GFP-tagged
PfCRT following induction of protein expression to a final
concentration of 5 mg/mL and incubated for 3 h. Live cell
imaging or an IFA was performed as previously described. As a
negative control, a second parasite culture was prepared in the
same way, treating with the same volume of ethanol instead of
Brefeldin A.
Protein expression of GFP-tagged PfCRT was induced and
young trophozoite or schizont parasites were treated with
40 mmol/L Dynasore (200 mM dissolved in 100% (w/v) DMSO)
for 2 h. Live cell imaging or an IFA was performed as previously
described. A second parasite culture was prepared in the same
way, however instead of Dynasore hydrate the same volume of
100% (v/v) DMSO was added.
Chloroquine drug sensitivity assays
The drug sensitivity assays were performed using the SYBR
Green staining method after 48 hours of growth as previously
described by Smilkstein et al. [51] with some modifications as
detailed in [52].
Protein expression of sensitive and resistant form of PfCRT as
GFP-fusion protein in 3D7 P. falciparum parasites was induced as
described above. A second corresponding parasite population was
treated equally, yet maintained in the presence of the transcription
inhibitor ATc. Wild type 3D7 and W2mef parasites were also
assayed. Parasites of each population were dispensed to a final
parasitaemia of 0.5% in triplicate to a 96-well tissue culture plate
prepared with varying CQ concentration, 2% haematocrit, 10 mM
selective agent WR99210 and in the case of uninduced parasites,
0.5 mg/mL ATc in a total volume of 200 mL. For relevant
experiments, parasites were also cultured in 5 mM verapamil.
Parasite growth of induced and uninduced parasites was also
measured in the absence of CQ (positive control), and uninfected
erythrocytes cultured in the absence of CQ, WR99210 and ATc
provided the background level of fluorescence (negative control).
Parasites were cultured for 48 h under optimal culturing
conditions. Following the 48 h incubation period, CQ-treated
parasites were washed, added to a new 96-well tissue culture plate
containing SYBR Green I (Invitrogen) in lysis buffer (20 mM Tris
pH 7.5, 5 mM EDTA, 0.008% (w/v) saponin, 0.08% (w/v) Triton
X-100) and incubated for 1 h at RT. Fluorescence, with excitation
and emission wavelength centred at 485 nm and 530 nm
respectively, was examined using a ThermoScientific Varioskan
Flash Microplate Reader. Experiments were conducted in
triplicate, and each such experiment was performed independently
five times.
The Plasmodium Food Vacuole and PfCRT
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Expression of PfCRT
S and PfCRT
R as GFP-fusion protein
To investigate the phenotype of chloroquine sensitive parasites
expressing a resistant form of PfCRT without a delay that would
allow cryptic compensatory mutations and epigenetic changes
[32], we generated ATc-regulatable constructs with PfCRT fused
to GFP. We took advantage of the TATi3 transactivator system
established by Meissner and colleagues that allows repression of
expression by addition of ATc [44]. The original ATc-regulatable
plasmid expressed the transactivator under the control of the
promoter of PfMSP2 (PF3D7_0206800) [44], a gene with a
temporal transcription peak in schizont stage parasites. To mimic
the temporal expression of PfCRT we modified the TATI3 vector
by replacing the PfMSP2 with the promoter of PfPTEX150
(PF3D7_1436300), a gene with very similar expression phase and
abundance to PfCRT [53,54]. GFP fusions were generated for the
full gene of PfCRT from the chloroquine sensitive line 3D7 and
the chloroquine resistant line 7G8, which contains, among other
mutations, the K76T replacement (Figure 1A). Western blot
analysis using an anti-GFP antibody against mixed parasite
showed a band at a height corresponding to motility of
,62 kDa products in the induced parasites, but not in uninduced
samples (Figure 1B). 62 kDa is slightly smaller than the expected
molecular weight of 76 kDa for PfCRT as a GFP fusion but multi-
spanning TM proteins regularly migrate more quickly than
expected from their apparent mass, and PfCRT alone was
previously reported to migrate faster than expected [22]. These
analyses validated this expression system for the inducible
production and localisation of PfCRT
S and PfCRT
R (Figure 1C).
Localisation of GFP-tagged PfCRT
S and PfCRT
R to the FV
membrane
Previous localisation studies of PfCRT
S have reported localisa-
tion solely to the FV membrane [22,33]. However, our
bioinformatic analysis of PfCRT
S and PfCRT
R predicted a
possible difference in the length of the first TMD between
resistant and sensitive proteins, associated with the mutations at
position 76. Two independent TMD predictors, MEMSAT [40]
and SPLIT4 [41], predicted that the mutations found in the
PfCRT proteins of the resistant parasites DD2 or 7G8 (particularly
changes at k76) would change the length, position and polar face
of the first transmembrane domain (Figure 2A, B, C). Even small
differences in TMD composition or length can be enough to
mistarget proteins in the early stages of the secretory pathway
[34,35,42,55]. We therefore investigated whether the K76
mutations in PfCRT altered trafficking to the FV, which may
impact its role in modulating drug resistance.
Live cell fluorescence as well as immunofluorescence assays
were performed using the induced PfCRT
S-GFP fusion protein.
These localisation studies confirmed the localisation of PfCRT
S to
the FV membrane (Figure 1C). Occasionally, parasites showed a
minor additional fraction at the nuclear periphery, corresponding
to patterns previously described for ER localisation [33]. The
fluorescence signal remained strong over the whole intra-
erythrocytic life stages. PfCRT-GFP in schizont stage parasites
additionally localised to mobile puncta within the FV, as well as
labelling at the FV membrane. This may represent internalised
vesicles carrying PfCRT-GFP, or GFP alone after degradation of
the fusion protein, although we did not see a GFP-only band by
western blot.
The localisations of both PfCRT
S and PfCRT
R were simulta-
neously analysed and compared repeatedly, but no differences in
the localisation were observed between the two at any life stage
(Figure 1). Both forms show a clear and restricted localisation to
the FV membrane, including the particularities mentioned above,
such as occasional ER staining and puncta within the FV lumen in
older parasites. These results confirmed that the inducible
expression system used in this study was capable of expressing
both forms of PfCRT as GFP-fusions and that the K76T mutation
does not result in any altered localisation of PfCRT.
Development of the FV during the intra-erythrocyte life
stages
The focus of previous studies of PfCRT were either its
localisation or trafficking to the FV membrane [22,33] and these
studies focused on trophozoite parasites because the FV was
apparent during this life cycle stage and allowed co-localisation
with the haemozoin crystal. We therefore wished to extend these
studies by using the PfCRT-GFP fusion as a marker of FV
development throughout the asexual intra-erythrocytic life cycle.
The first expression of GFP-tagged PfCRT
S in induced parasites
was detected as a juxta-nuclear dot-like structure in mid to late
rings (Figure 3A). In mid ring parasites a dual localisation between
the nascent FV and the ER was frequently observed, indicated as a
juxta-nuclear puncta structure as well as a fine ring around the
nucleus. In late ring stage parasites, the small sphere of
fluorescence co-localises with a round spherical body that is visible
by light microscopy, yet at this stage still lacks any detectable
refractile or dark haemozoin crystal. This indicates that a discrete
pre-FV compartment, bearing PfCRT, forms prior to the
appearance of haemozoin, which is normally used as a morpho-
logical character to define commencement of the trophozoite stage
(Figure 3A).
This stage was followed by enlargement of the PfCRT-
delineated vacuole, then continued expansion of both the
haemozoin crystal and the vacuolar membrane. In mature
schizont stages, a second PfCRT
S-GFP-labelled structure was
observed that enlarged into a small ring structure that was either
attached to the FV membrane or separate from the FV membrane
(Figure 3A, B). This second ring structure, if not adjacent to the
FV membrane, had no association with the FV whatsoever and
seemed to be an independent organellar compartment itself.
Haemozoin crystal was also apparent within these secondary FV-
like compartments (Figure 3B). In summary, live cell microscopy of
PfCRT-GFP parasites reveals the presence of a pre-FV compart-
ment prior to detection of haemozoin crystal. This compartment
may originate from the parasite periphery, but is also consistent
with previously-described dynamic processes during late stage
parasites that result in a second FV compartment originating from
the FV [7,56].
Analysis of the targeting processes of GFP-tagged PfCRT
S
Inducibly expressed GFP-tagged PfCRT
S was used to investi-
gate the trafficking route of PfCRT to the FV membrane. The
treatment of parasites over-expressing PfCRT
S-GFP with BFA
was performed in order to confirm the use of the inducible system
for trafficking studies using GFP-tagged PfCRT
S [33]. BFA
treatment of mainly trophozoite and schizont stage parasites was
performed as previously described for 3 h with 5 mg/mL BFA
[33]. Whereas the control population treated only with the
equivalent volume of ethanol, showed a restricted FV membrane
localisation (Figure 4A), the BFA-treated parasites showed a
marked increase in fluorescence around the nucleus, correspond-
ing to ER localisation (Figure 4B). As with the untreated parasites,
there was no accumulation or labelling of PfCRT
S molecules at
either the PPM or a Golgi-like compartment. These results were
The Plasmodium Food Vacuole and PfCRT
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38781Figure 1. Over-expression of sensitive and resistant form of PfCRT as GFP-fusion protein. (A) Schematic representation of the inducible
expression plasmid pT150KPfCRTGFP. Expression of the transcription activator TATi3 is under the control of the 5’ UTR of PTEX150. In the presence of
the transcription inhibitor anhydrotetracycline (ATc), TATi3-binding to the Tet operon (TetO) is inhibited and no expression of GFP-tagged PfCRT
occurs. In the absence of ATc, TATi3 binds to TetO, initiating the over-expression of PfCRT-GFP. Cam5’: 5’ UTR of Calmodulin, hDHFR: human
dihydrofolate reductase. (B) Western Blot analysis of induced over-expression of sensitive (PfCRT
S) and resistant (PfCRT
R) form of PfCRT as GFP-fusion.
Presence of PfCRT
S and PfCRT
R as GFP-fusions, labelled with mouse anti-GFP, is confirmed by the presence of a band at 62 kDa only in the parasites
cultured in the absence of ATc. P. falciparum wild-type strain 3D7 represents the negative control. Labelling with rabbit anti-GAPDH shows equal
loading in these lanes. (C) Fluorescence microscopy of GFP-fusions of sensitive (PfCRT
S, top) and resistant (PfCRT
R, bottom) form of PfCRT. PfCRT
S and
PfCRT
R were over-expressed as GFP-fusion proteins using an ATc-inducible expression system. Live cell images of DAPI-stained infected red blood
cells show that both forms of PfCRT localise to the FV membrane. Later stages of the asexual life cycle show ring/dot-like structures (white arrow)
within the FV, possibly degraded GFP-fusion proteins.
doi:10.1371/journal.pone.0038781.g001
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of PfCRT [33].
To investigate a role for dynamin-mediated vesicle formation in
the trafficking of PfCRT
S, we treated GFP-tagged PfCRT
S
expressing parasites with the dynamin GTPase inhibitor Dyna-
sore. Previous studies localised PfDYN1(PF3D7_1145400) to the
ER and FV, whereas PfDYN2 (PF3D7_1037500) was localised to
the ER and Golgi compartment [57,58] and Dynasore treatment
was reported to disrupt the integrity of the FV, producing a
fragmented organelle [50]. We treated malarial parasites express-
ing GFP-tagged PfCRT
S for 2 h with a concentration of 40 mM, a
concentration reported to reduce GTPase activity of both
dynamin-like enzymes by approximately 50%, but which enabled
the parasites to develop to later stages [50], whereas a
concentration at 80 mM completely inhibited the development of
the parasites. Analysis of parasites cultured longer than 2 h in the
presence of Dynasore did not show any clear differences in
morphology and labelling pattern compared to the 2 h treatment
(data not shown). Fluorescence in parasites treated with Dynasore
was somewhat lower, indicative of some toxicity, as seen with BFA.
Immunofluorescence showed that while there was GFP at the FV
membrane, there was also an increased accumulation of PfCRT
S-
GFP around the nucleus in the treated parasites, corresponding to
ER localisation (Figure 4C). Some dynasore-treated parasites
showed a pattern of PfCRT
S that did not perfectly co-localise with
the FV but which formed a long string-form associated with the
exterior of the FV without embracing the whole FV as in the
untreated parasites. These data indicate that the trafficking of
PfCRT is via the ER and not only involves BFA-sensitive
processes, as previously shown [33], but also the action of
dynamin-like proteins.
Phenotypic analysis of malarial parasites over-expressing
PfCRT
S and PfCRT
R
Parasites inducibly over-expressing GFP-fusions of PfCRT
S and
PfCRT
R were used to investigate differences in sensitivity to CQ.
These parasites each possessed two separate PfCRT proteins – the
unmodified genomic copy of PfCRT
S in the 3D7 line, as well as
the GFP-fusion of either PfCRT
S (from 3D7) or PfCRT
R (from
7G8). Because episomes are poorly segregated in P. falciparum,
some parasites in any generation of a transfected line do not
express the desired product. In addition, the inducible system is
imperfect, and only a small number of parasites strongly express
the induced protein, as found in previous implementations of this
system [44]. Moreover, expression of the PfCRT-GFP fusion
became considerably weaker several cycles after induction,
precluding longer-term experiments, or establishment of parasites
stably expressing the fusion protein. The reason for this is unclear,
but may relate to toxicity of longer expression of the PfCRT-GFP
fusions. These variables meant that it was important to carefully
measure the number of parasites expressing the PfCRT-GFP
fusion in each line during the drug sensitivity assays, and to
Figure 2. Bioinformatic analysis of the K76T mutation in PfCRT. (A) Multiple sequence alignment (by Jalview [38]) of the first TMD of CQ-
sensitive D10 and CQ-resistant 7G8 and Dd2 parasites [22]. The amino acids are represented according to their hydrophobicity (hydrophilic residue
(blue), hydrophobic residue (red), intermediate stages (dark red, violet)). The mutation at position 76 represents a replacement of a positively
charged, hydrophilic residue (lysine, K) with an uncharged, hydrophobic (threonine, T) residue. (B) Predicted length of the first TMD of sensitive and
various resistant alleles of PfCRT using different bioinformatic predictors. Single point mutations at position 76 [22,63] were analysed using three
different TM prediction applications, i.e. TMHMM2 [39], Memsat [40] and Split4 [41]. Following the TM prediction the predicted length and position of
the first TMD of PfCRT were extracted and analysed. In contrast to TMHMM2, the predictors Memsat and Split predict a change in both length and
position due to a single point mutation at position 76. (C) Helical wheel projection of the first TMD of Glycoprotein M (left) and PfCRT (right). Yellow
residues are nonpolar; green residues are polar, uncharged; blue residues are basic. The first TMD of the infectious bronchitis virus Glycoprotein M
consists of a polar face (black square around the involved residues) within its first TMD that becomes obvious when represented in a helical wheel
projection (modified from [42]). Point mutations that modified the polar face of the TMD resulted in a mistargeting of the viral Glycoprotein M [42].
Helical wheel projection of the first TMD of PfCRT reveals a change in the polar face as a result of mutations at position 76 (modified from [62]).
doi:10.1371/journal.pone.0038781.g002
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induction. After fusion protein induction by removal of the
transcription inhibitor ATc from sorbitol-synchronised ring stages,
parasites were allowed to over-express PfCRT
S-GFP or PfCRT
R-
GFP until the next ring stage after synchronisation, at which point
the CQ drug assay was commenced. To assess consistency of
PfCRT-GFP fusion expression, fluorescence (of induced parasites)
was monitored and the percentage of GFP-expressing parasites
determined in separate plates a further 12 hours later. On average
7.760.4% and 8.360.8% of parasites were fluorescent in the
PfCRT
S-GFP and PfCRT
R-GFP lines, respectively. This result
confirmed the consistency of the inducible expression system and
additionally demonstrated comparable proportions of over-
expressing parasites in the two independent populations after
ATc removal.
Parasite sensitivity to CQ was followed using a SYBR-Green
assay of parasite growth over 48 hours, with the WR99210
selective agent maintained in transfected parasites. From a total of
five independent experiments, each with three internal replicates,
the IC50 value for 3D7 wild-type parasites using this experimental
method was on average 18.963.8 nM, and W2mef parasites had
an IC50 for chloroquine of 295.3621.0. (Table 1) These IC50
values are consistent with 48 hour IC50s previously reported for
these strains [59,60]. Parasites transfected with the PfCRT-GFP
plasmids but with transgene expression repressed by maintenance
on ATc showed no significant difference in the IC50 compared to
3D7 (t-test p.0.05). No significant difference in chloroquine
sensitivity was observed between these parasites and parasites
expressing either PfCRT
R-GFP or PfCRT
S-GFP (t-test p.0.05).
Verapamil, a chloroquine-resistance reversing agent, restored
Figure 3. Analysis of the de novo biogenesis and development of the FV in live cells using PfCRT-GFP as a marker of the FV
membrane. PfCRT was over-expressed as a GFP-fusion protein using an ATc-inducible expression system. (A) Live DAPI-stained cells were imaged.
The earliest detectable and distinct localisation of PfCRT-GFP was observed in mid ring stage parasites, co-localising with a round spherical shape in
proximity to the DAPI-stained nucleus. The characteristic dark haemozoin crystal was not yet visible in these parasites. In addition to FV labelling,
some fluorescence was detectable at the ER. PfCRT-GFP labelling of the FV membrane was observed throughout the whole intra-erythrocytic life
cycle. In accordance with an increase of the haemozoin crystal, the ring-like labelling of the FV membrane expanded as the parasite grew. An
unexpected second PfCRT-GFP-labelled sphere was observed in schizont stage parasites. In some parasites this additional structure was associated/
attached to the FV membrane (lower schizont panel). (B) An overlay with the corresponding brightfield (BF) image shows that in some parasites the
additional PfCRT-GFP enclosed compartment (white arrow) is separate from the FV and surrounds a dark structure, possibly haemozoin.
doi:10.1371/journal.pone.0038781.g003
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discernible effect on the CQ sensitivity of the PfCRT
R-GFP or
PfCRT
S-GFP expressing lines (Table 1) (t-test p.0.05). We
conclude, therefore, that these fusion proteins either have no
impact on chloroquine resistance, or a sufficiently mild effect that
our drug-response assay is unable to detect it.
Discussion
The food vacuole membrane protein PfCRT is a major
modulator of chloroquine resistance [22]. The molecular basis of
chloroquine resistance is still debated, but a likely mechanism is
that mutations in PfCRT modify this transporter or channel so
that it allows chloroquine to leak out of the FV. PfCRT from
chloroquine resistant parasites bear mutations including an
apparently crucial substitution of the lysine at position 76
[61,62,63]. Mutant, but not wild type PfCRT has been shown
to transport chloroquine in Dictyostelium and Xenopus ooocyte models
[30,64]. Here we have studied PfCRT from resistant and sensitive
parasites in P. falciparum by generating parasite lines with ATc-
regulatable overexpression of these full-length PfCRT proteins
fused to GFP. These parasites were used to address three
questions; 1) Do mutations in the transmembrane domain of
PfCRT alter its trafficking characteristics and thereby influence
chloroquine sensitivity; 2) How does a model FV membrane
protein traffic to the FV? and 3) Is over-expression of PfCRT from
a resistant line sufficient to bestow CQ resistance in the genetic
and epigenetic background of a CQ-sensitive parasite? The tools
we developed proved to be insufficient to conclusively address the
Figure 4. Immunofluorescence microscopy of PfCRT-GFP over-expressing parasites treated with either Brefeldin A or Dynasore.
PfCRT was over-expressed as a GFP-fusion protein using an ATet-inducible expression system and treated with either BFA (5 mg/mL) for 3 h or
Dynasore (40 mM/mL) for 2 h. As a control a second parasite population was treated with an equivalent volume of carrier alone (ethanol and DMSO,
respectively). Following the BFA treatment, immunofluorescence microscopy was performed on fixed cells with mouse anti-GFP, Alexa-594 goat anti-
mouse IgG and DAPI. Representative parasites in trophozoite and schizont stage are shown for control and treated parasites. (A) The control parasites
show the restricted FV localisation of PfCRT-GFP (false-coloured in green). (B) BFA treated parasites show an accumulation of fluorescence around the
DAPI-stained nuclei, consistent with ER localisation in addition to the FV localisation (Figure 1). (C) Treatment of parasites with Dynasore resulted in
an accumulation of fluorescence around the DAPI-stained nuclei in addition to the FV membrane localisation, similar to the observed effect of BFA
treatment (B).
doi:10.1371/journal.pone.0038781.g004
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two questions.
Is the subcellular localisation of PfCRT
S identical to
PfCRT
R at the FV membrane?
Experiments in other eukaryotic systems have increasingly made
clear the important role of TMDs in positioning a protein within
the cell. For proteins in the endomembrane system, the
composition and length of the transmembrane domains, particu-
larly the initial membrane-spanning domain, can partially
determine their subcellular localisation [34,35,36,42,55,65].
Changes that result in mis-targeting include mutations that alter
the length of a transmembrane domain [35], or which add or
remove a polar face to a transmembrane domain (eg [42])
(Figure 2C). Specific transmembrane domains have also been
shown to be instrumental in trafficking in Plasmodium falciparum
[66,67]. The major resistance determining mutation in PfCRT is
at the end of the first predicted transmembrane domain [22], and
multiple additional mutations are found in other transmembrane
domains of PfCRT that modulate resistance to chloroquine and
other quinolone drugs [62]. Bioinformatic interrogation of these
mutations suggest that they may alter the position and length of
the initial transmembrane domain (Figure 2). We therefore tested
whether changes in these transmembrane domains may modulate
resistance to Plasmodium by changing the subcellular localisation of
PfCRT – potentially altering subcellular distribution of chloro-
quine by changing relative amounts of the transporter on the food
vacuole, plasma membrane or ER/Golgi. Our examination of
identically-prepared GFP fusions of resistant and sensitive forms of
PfCRT conclusively falsifies this hypothesis – there was no
difference in abundance or localisation between the two forms,
and both were exclusively intracellularly localised, with no
detectable fraction at the plasma membrane.
A much more likely alternative is that the changes in charge and
potential orientation changes in the membrane spanning portion
of the protein brought about by changed TMD lengths result in an
altered transport capacity of PfCRT. Cooper and colleagues [62],
and Martin and Kirk, have convincingly described how the
diminished positive charge at this limit of the PfCRT TMDs polar
face [68] might change the transporter’s affinity for protonated
CQ
2+. The increased ability of the PfCRT
R to transport
chloroquine in heterologous systems is strongly supportive of this
model [30,64].
How does PfCRT traffic to the FV?
We used the inducible PfCRT-GFP fusions to investigate the
trafficking route of induced protein to the FV membrane. Kuhn
and colleagues have previously demonstrated that PfCRT traffic to
the FV membrane is via the ER/Golgi using a combination of
genetic deletion experiments and treatment of parasites with the
fungal metabolite Brefeldin A (BFA) [33]. BFA interferes with
early targeting events between ER and Golgi level by inhibiting
the function of guanine nucleotide-exchange (GEP) proteins that
regulate the activation of ADP-ribosylation factor (Arf) proteins
[69,70]. Arf proteins are involved in a wide range of functions,
including regulation of ER and Golgi function and morphology,
ER-to-Golgi transport, and recruitment of COP and adaptor
protein complex proteins (reviewed in [71]). We also examined the
BFA sensitivity of the inducibly expressed PfCRT-GFP fusion, and
found that BFA produced a defect in traffic from the ER/Golgi to
the FV membrane, consistent with a trafficking route via the ER/
Golgi (Figure 4). One means of trafficking vesicles from the ER
and Golgi is through dynamin and dynamin-like GTPase-
mediated vesicle budding [72,73,74,75]. Plasmodium has several
dynamin-like proteins, some likely involved in organelle division
and endocytosis, and others potentially involved in vesicle budding
[58,76,77]. One of these dynamin homologues – PfDYN1
localised to multiple cellular destinations including the FV and
the ER [58], while another, PfDYN2 was reported to localise to
the ER, Golgi compartment and the relict plastid [57]. Roles for
dynamin-like GTPases in Plasmodium have been interrogated using
Dynasore, a non-competitive inhibitor that acts on the dynamin
GTPase domain [78]. Dynasore has been reported to produce a
dramatic effect on Plasmodium endocytosis and haemoglobin
uptake, as well disrupting leading to profound fragmentation of
the FV [50].
We addressed whether dynamin-like GTPases are involved in
the targeting of PfCRT to the FV by Dynasore-treating parasites
that over-expressed PfCRT
S-GFP. In contrast to a previous study
[50], we saw no widespread morphological defects of the FV,
assayed by live cell imaging of parasite with the FV membrane
highlighted by PfCRT
S-GFP labelling (figure 4C). In our
experiments the FV was intact and not fragmented. We did
however see some disruption of PfCRT
S-GFP targeting, with an
increase of fluorescence around the nuclei, corresponding to ER
localisation (figure 4C). This suggests that dynamin-like proteins
may be involved in the trafficking of proteins from the ER/Golgi
to the FV, potentially through its action in completing budding of
vesicles. These data also independently support the model of an
ER-mediated trafficking mechanism for FV membrane proteins.
How does the food vacuole develop?
The FV does not persist throughout the intra-erythrocytic life
stages and hence depends on de novo biogenesis following the
invasion of each new erythrocyte. Current models that try to
describe how the FV de novo biogenesis occurs [5,6,7] and how this
endosomal/lysosomal-like organelle develops over the intra-
erythrocytic life cycle [79,80] are based on observations from
various microscopic techniques. The availability here of a
fluorescent marker of the FV membrane meant that we were
able to identify mid to late ring stage parasites – even before
haemozoin crystals are present – as the earliest parasites with a
defined FV compartment. Abu Bakar and colleagues showed the
existence of various small pre-FV compartments that fuse together
to form a central FV compartment [7]. Light microscopy likely
provides insufficient resolution for us to be able to identify whether
the earliest PfCRT labelling delineates one small compartment, or
multiple small vesicles aggregating. Experiments using fluorescent
Table 1. IC50 of different P. falciparum transgenic lines and
treatments after 48 hours chloroquine treatment.
Strain/treatment IC50±SD
3D7/PfCRT
RGFP uninduced 19.963.3
3D7/PfCRT
SGFP uninduced 19.263.6
3D7 PfCRT
RGFP induced 20.965.5
3D7 PfCRT
SGFP induced 19.663.5
3D7 PfCRT
RGFP induced + verapamil 18.161.7
3D7 PfCRT
SGFP induced + verapamil 17.661.7
3D7wt 18.963.8
3D7wt + verapamil 18.060.4
W2MEF 295.3621.0
W2MEF + verapamil 56.660.7
doi:10.1371/journal.pone.0038781.t001
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these earliest PfCRT-bound compartments already contain
haemoglobin.
The other interesting finding respecting FV cell biology was the
revelation of a second dot-like structure or ring structure beside the
FV ring localisation in later schizont stage parasites. Several
studies of the FV do indeed show neighbouring compartments that
might contain haemozoin, but it was unclear if those compart-
ments were protrusions of the FV whose connections were invisible
in 2 dimensions [56,61]. Instead, these smaller PfCRT-GFP
compartments share more similarities with long-lived extra-FV
compartments described by Abu Bakar and colleagues [7]. It is
unclear if these secondary compartments derive from parcels of
haemoglobin from the cytostomal invagination that have already
recruited PfCRT but have fail to fuse with the existing FV
membrane, or if they result from the pinching-off of a part of the
FV resulting in a second FV-like compartment.
Another possibility for the identity of these structures are neutral
lipid bodies, which are superficially similar in appearance. Neutral
lipid bodies can be visualised with the hydrophobic probe Nile
Red and they have been previously linked to haemozoin formation
[81,82]. In Plasmodium they have been found within the FV lumen
and in schizont stage parasites in the cytosol as well. However, an
association between PfCRT and neutral lipid bodies was not
detected in a western blot analysis of neutral lipid bodies [81].
Furthermore, in contrast to the multiple neutral lipid bodies seen
in individual schizonts [82] we saw only a single additional PfCRT
bound compartment in each cell. The substantial emission
spectrum overlap between Nile Red and GFP prevented
colocalisation experiments with PfCRT-GFP using available
imaging equipment.
Chloroquine sensitivity in PfCRT-GFP over-expressing
parasites
Despite the clear causal relationship between mutations in
PfCRT and chloroquine resistance, the role of additional genetic
and epigenetic factors in the acquisition of chloroquine remains
unclear. This is partly because other lines expressing transgenic
PfCRT [22] or with PfCRT allelic exchanges [63,83] have had
weeks of growth at least to compensate for any negative effects of
the mutant PfCRT [32]. We attempted to study whether sudden
expression of mutant, chloroquine resistant PfCRT in a sensitive
background was sufficient to bestow chloroquine resistance by
using the repressible ATc expression system. However, the IC50
values obtained for CQ sensitive 3D7 parasites over-expressing
either PfCRT
S-GFP or PfCRT
R-GFP showed no significant
difference. Several factors make these results difficult to interpret
- the first is that only a small percentage (only ,8–10%) of cells
expressed the fusion proteins after induction in either cell lines.
This effect has been seen before for ATc-regulatable systems in
apicomplexan parasites [44], and in our system meant that a large
number of the parasites being assayed were in fact parental
population, and any phenotypic signal emanating from the
induced parasites would have been weakened by the background
signal from the non-expressing parasites. Nevertheless, the gap in
drug sensitivity between strongly drug resistant and sensitive lines
is sufficient that substantial differences should still have been
apparent as a changed IC50 even in a mixed population. Another
possible confounding factor is that the GFP fusion to PfCRT may
prevent these from functioning as transporters, or may inhibit their
interaction with chloroquine. We had initially intended to study
inducibly over-expressed PfCRT forms without the GFP fusion to
investigate this effect. However, the very low levels of parasites
expressing after induction) meant such an experiment would have
been unreliable without a marker for the PfCRT overexpression.
Some PfCRT antibodies are available, but none were reliably
specific in our hands.
FACS based sorting of fluorescent parasites to purify popula-
tions of homogeneously expressing cells may represent another
potential experimental approach but the low number of cells
possible to recover in such a sorting experiment may be
inappropriate for use in a drug sensitivity assay. Development of
a superior inducible system in P. falciparum may also address these
issues. A conditional protein stabilisation system has been used to
excellent effect to address several questions of Plasmodium biology,
but the applicability of this system to all subcellular destinations is
uncertain [84,85].
Summary
PfCRT as a marker protein of the FV membrane has proven to
be an important tool to study the de novo biogenesis and
development of the FV in live Plasmodium parasites. However,
the exact process underlying the de novo biogenesis of the FV and
the mechanism by which haemoglobin is transferred to the FV
remain important questions to address. So too does the question of
how important compensatory mechanisms are for allowing
PfCRT mutations to mediate chloroquine resistance. The latter
question would be particularly facilitated by a superior inducible
expression system that enables robust interrogation of condition-
ally expressed PfCRT.
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